iRadimed (IRMD) Expected to Announce Earnings on Monday

iRadimed (NASDAQ:IRMD) will likely be posting its Q3 2025 results before the market opens on Monday, November 3rd. Analysts expect iRadimed to post earnings of $0.43 per share and revenue of $20.50 million for the quarter. Individuals may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Monday, November 3, 2025 at 11:00 AM ET.

iRadimed Stock Up 0.5%

Shares of IRMD stock opened at $76.81 on Friday. The stock has a market capitalization of $976.64 million, a PE ratio of 47.41 and a beta of 1.02. iRadimed has a 52-week low of $46.86 and a 52-week high of $80.64. The stock’s 50-day moving average price is $73.14 and its 200 day moving average price is $63.75.

Insider Buying and Selling

In related news, CEO Roger E. Susi sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, October 27th. The stock was sold at an average price of $77.69, for a total value of $388,450.00. Following the sale, the chief executive officer owned 2,327,500 shares of the company’s stock, valued at approximately $180,823,475. This represents a 0.21% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Monty K. Allen sold 1,102 shares of iRadimed stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $69.10, for a total value of $76,148.20. Following the completion of the sale, the director directly owned 19,898 shares of the company’s stock, valued at approximately $1,374,951.80. This represents a 5.25% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 36,102 shares of company stock worth $2,623,848. 36.80% of the stock is owned by corporate insiders.

Institutional Trading of iRadimed

Several large investors have recently added to or reduced their stakes in IRMD. Tower Research Capital LLC TRC lifted its position in shares of iRadimed by 191.1% during the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 495 shares during the last quarter. Osaic Holdings Inc. lifted its position in shares of iRadimed by 766.6% during the second quarter. Osaic Holdings Inc. now owns 3,813 shares of the medical equipment provider’s stock worth $228,000 after purchasing an additional 3,373 shares during the last quarter. Prudential Financial Inc. bought a new position in shares of iRadimed during the second quarter worth about $240,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of iRadimed by 5.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock worth $252,000 after purchasing an additional 234 shares during the last quarter. Finally, Brevan Howard Capital Management LP bought a new position in shares of iRadimed during the second quarter worth about $260,000. 92.34% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

IRMD has been the topic of several recent analyst reports. Weiss Ratings reiterated a “buy (b)” rating on shares of iRadimed in a research report on Friday. Wall Street Zen cut iRadimed from a “strong-buy” rating to a “buy” rating in a research report on Sunday, October 26th. Finally, Roth Capital set a $90.00 target price on iRadimed in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $81.00.

iRadimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.